Anzeige
Meldung des Tages: Der Vorteil des Meeresbodens: Wie Tiefsee-Knollen den landbasierten Bergbau übertreffen könnten

Inventiva News

Aktie
WKN:  A2DLV9 ISIN:  FR0013233012 US-Symbol:  IVEVF Branche:  Biotechnologie Land:  Frankreich
4,745 €
+0,145 €
+3,15%
10:43:57 Uhr
Depot/Watchlist
Marktkapitalisierung *
328,73 Mio. €
Streubesitz
40,63%
KGV
-4,80
Index-Zuordnung
-

Inventiva News

24.09.25 - GlobeNewswire
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned ...
04.09.25 - GlobeNewswire
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage ...
11.08.25 - GlobeNewswire
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
31.07.25 - GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage biopharmaceutical ...
29.07.25 - GlobeNewswire
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Cash and cash equivalents at €122.1 million and €24.6 million in short-​term deposits 2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City ...
09.07.25 - GlobeNewswire
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, ...
07.07.25 - GlobeNewswire
Inventiva receives $10 million milestone payment from CTTQ
Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
02.07.25 - GlobeNewswire
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Analysis of liver sinusoidal endothelial cells (“LSEC”) from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in ...
10.06.25 - GlobeNewswire
Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors
Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
27.05.25 - GlobeNewswire
Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference
Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
23.05.25 - GlobeNewswire
Inventiva reports 2025 First Quarter Financial Information¹
Cash and cash equivalents at €67.9 million Daix (France),  New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a ...
23.05.25 - GlobeNewswire
Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025
Daix (France), New York City (New York, United States), May 23, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
22.05.25 - GlobeNewswire
Description of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler Chevreux
Daix, May 22, 2025
05.05.25 - GlobeNewswire
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City ...
30.04.25 - GlobeNewswire
Combined General Meeting of May 22, 2025 - Availability of the preparatory documents
Daix (France), New York City (New York, United States), April 30,  2025 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-​stage biopharmaceutical company focused on the ...
30.04.25 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2025
Article R. 22-10-23 of the French Commercial Code
24.04.25 - GlobeNewswire
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis

Newssuche

Videos

newspaper
16.04.26 +0,31%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »